Log inStart free trialBook a demo
Log inStart free trial
Media Database
>
Jacob Bell

Jacob Bell

Senior Reporter at BioPharma Dive

Contact this person
Email address
j*****@*******.comGet email address
Influence score
45
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Languages
  • English
Covering topics
  • Biotechnology
  • Health & Medicine

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

biopharmadive.com

AC Immune posts positive data for Parkinson’s immunotherapy

Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug regulators for feedback to “potentially accelerate” the time to an approval filing. 
12 days ago
biopharmadive.com

UniQure slides further on outlook for Huntington’s gene therapy

Finalized minutes from a late-October meeting with the FDA confirm the agency doesn't see the data collected so far as enough to support an approval filing.
19 days ago
biopharmadive.com

An Arch-backed biotech raises $53M to fight neurodegeneration

SciNeuro Pharmaceuticals represents the latest in a string of Arch investments directed at the nervous system, a notoriously challenging area of drug development.
19 days ago
biopharmadive.com

The ‘clever’ tool increasingly getting bigger biotech deals signed

A decades-old way to bridge buyers and sellers on price, contingent value rights have recently seen an uptick in use due to a turbulent biotech market.
21 days ago
biopharmadive.com

Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s stu...

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help combat neurodegeneration.
29 days ago
biopharmadive.com

A brain biotech’s top drug fails against MS

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for a drug that’s also piqued Johnson & Johnson’s interest.
about 1 month ago
biopharmadive.com

Merck’s blockbuster-to-be cardiovascular drug scores in another hea...

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.
about 1 month ago
biopharmadive.com

Roche’s MS tablet scores in late-stage studies

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts question if Roche has collected enough data to ask for approval in the latter.
about 1 month ago
biopharmadive.com

Knocked back by the FDA, Biohaven turns to major cost cuts

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.
about 2 months ago
biopharmadive.com

Vertex’s new pain, blood disorder drugs miss Wall Street expectations

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.
about 2 months ago
biopharmadive.com

Roche taps an AI specialist to craft new brain drugs

Roche taps an AI specialist to craft new brain drugs
about 2 months ago